Profitability Ratios
| Ratio |
Value |
| GP Margin |
73.3% |
| EBIT Margin |
-13.0% |
| EBITDA Margin |
-11.5% |
| Operating Margin |
-1.6% |
| Pretax Margin |
-13.0% |
| Cont. Ops Margin |
-13.0% |
| Net Margin |
-13.0% |
| Bottom Line Margin |
-13.0% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.48 |
| Quick Ratio |
1.51 |
| Solvency Ratio |
-0.074 |
| Cash Ratio |
0.30 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.31 |
| Forward PEG |
-0.31 |
| Price/Book |
15.12 |
| Price/Sales |
1.40 |
| Price/FCF |
-7.77 |
| Price/Op Cash Flow |
-7.85 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.5496 |
| Debt/Equity |
9.8122 |
| Debt/Capital |
0.9075 |
| Long-Term Debt/Capital |
0.9075 |
| Financial Leverage |
17.85 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.19 |
| Operating Cash Flow Ratio |
-0.287 |
| Operating Cash Flow/Sales |
-17.8% |
| Free Cash Flow/Operating Cash Flow |
101.1% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
0.00 |
| Interest Coverage |
0.0000 |
| Short-Term Operating Cash Flow Coverage |
0.00 |
| Operating Cash Flow Coverage |
-0.20 |
| Capital Expenditure Coverage |
-87.04 |
| Dividend + Capital Expenditure Coverage |
-87.04 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.93 |
| EPS |
-0.121 |
| Debt/Share |
0.8436 |
| Cash/Share |
0.28 |
| Book Value/Share |
0.09 |
| Tangible BV/Share |
0.09 |
| Equity/Share |
0.09 |
| Operating Cash Flow/Share |
-0.166 |
| Capital Expenditure/Share |
0.002 |
| FCF/Share |
-0.167 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
7.957 |
| Price/Fair Value |
15.12 |
| Debt/Market Cap |
0.6489 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-18.38 |
HRTX - Heron Therapeutics, Inc.